Accredited Activity

Learning Objectives

Upon completion of this activity, participants should be able to:

• Outline the latest clinical data evaluating the efficacy and safety of second-generation anti-VEGF therapies for diabetic retinopathy (DR)/DME
• Determine a management plan to initiate or switch to a second-generation anti-VEGF therapy when appropriate for patients with DR/DME

Faculty & Disclosures

Faculty
David S. Boyer, MD
Retina-Vitreous Associates Medical Group
Los Angeles, CA

Diana V. Do, MD
Vice Chair of Clinical Affairs
Professor of Ophthalmology
The Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA

Scientific Integrity and Disclosure of Financial Interest
The American Academy of Ophthalmology is committed to ensuring that all continuing medical education (CME) information is based on the application of research findings and the implementation of evidence-based medicine. It seeks to promote balance, objectivity, and absence of commercial bias in its content. All persons in a position to control the content of this activity must disclose any and all financial interests. The Academy has mechanisms in place to resolve all conflicts of interest prior to an educational activity being delivered to the learners.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the Academy requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to the Academy’s policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. The Academy is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest.

A full listing of financial disclosures can be found below. All relevant relationships have been mitigated.

Faculty:
David S. Boyer, MD
Consultant/Advisor: 4DT; Abbvie; AdaRx; Adverum Biotechnologies; Aerpio; Alcon Pharmacueticals.; Alkahest; alkeus; Allegro Ophthalmics, LLC; Allergan, Inc.; Allgenesis; Alzehon; Amgen Inc; Annexon; Apellis Pharmaceuticals, Inc.; AsclepiX Therapeutics; Bausch + Lomb; Bayer Healthcare Pharmaceuticals; BioCryst; Biogen International Gmbh; BioMotiv; BioTime Inc.; Boehringer Ingelheim; Chengdu Kanghong Biotec; Clearside Biomedical, Inc.; Coda Therapeutics, Inc.; Daiichi Sankyo Co. LTD; Duet; Everads Therapy Ltd; EyePoint Pharmaceuticals; Galimedix Therapeutics, Inc.; GENENTECH; GenSight Biologics; Glaukos Corporation; Horizon Healthcare Group; Humonix; Iconic Therapeutics Inc; InflammX; Interface Biologics, Inc.; Ionis; Iveric Bio; Jcyte; Kala Pharmaceuticals, Inc.; Kyowa Kirin; Lucia; Lumithera; Nanoscope; Neurotech USA; NGM; Novartis Pharmaceuticals; Ocugen, Inc; Ocular Therapeutix; Ocuphire Pharma Inc; OcuScience; Opthea; Optigo; Optos, Inc.; Opus; Ora, Inc; Oxurion; perceive; perfuse; Ray Vision, Inc.; Reazolute; RecensMedical Inc; Regeneron Pharmaceuticals, Inc.; REGENXBIO; Regulus Therapeutics; Samsung; Samumed, LLC; Sandoz; Sanofi; Santen, Inc.; Semathera; Smilebiotek; Stealth Biotherapeutics; Sun Pharmaceutical Industries; THEA; Unity; vitraneu
Grant Support: Alcon Pharmaceuticals; Novartis Pharmaceuticals; Ocular Therapeutix
Stock Options: Jcyte; InflammX; Ocugen, Inc

Diana V. Do, MD
Consultant/Advisor: 4DMT; Adverum; Apellis Pharmaceuticals, Inc.; Bayer Healthcare Pharmaceuticals; Belite Bio; Boehringer Ingelheim; Eyepoint; GENENTECH; Iveric Bio; Kodiak Sciences Inc.; Kriya Therapeutics; Lumithera; Regeneron Pharmaceuticals, Inc.; Regenxbio
Grant Support: Belite Bio; Boehringer Ingelheim; Lumithera; Regeneron Pharmaceuticals, Inc.; Regenxbio
Equity/Stockholder—Public Corp: Belite Bio; Kodiak Sciences Inc.

Content Reviewer:
Jay C. Wang, MD
Consultant/Advisor: Carl Zeiss Meditec

The American Academy of Ophthalmology and Paradigm staff members have no relevant financial relationships with ineligible companies to disclose.

CME Information

CME for Physicians
The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement
The American Academy of Ophthalmology designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Participation
To receive a certificate and claim credit, participants must:

• Follow instructions to register or log in with your professional information and complete the pretest
• View the online activity in its entirety
• Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact The American Academy of Ophthalmology at cme@aao.org.

There are no fees for participating in this activity.

Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support
If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, The American Academy of Ophthalmology or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, The American Academy of Ophthalmology must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by The American Academy of Ophthalmology.

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by The American Academy of Ophthalmology or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by The American Academy of Ophthalmology or Paradigm Medical Communications, LLC. The American Academy of Ophthalmology and Paradigm Medical Communications, LLC accept no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program and may be used to track registration and participation. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.

© American Academy of Ophthalmology 2026 except where noted. Content may not be reproduced in whole or part without the express written permission of the American Academy of Ophthalmology.